Background. The role of intravenous immunoglobulin (IVIG) as an adjunctive treatment for severe sepsis remains controversial. We hypothesized that IVIG could be effective for treating pneumonia patients who have septic shock.
Despite recent developments in the diagnosis and treatment of sepsis, mortality rates in patients with severe sepsis and septic shock remain unacceptably high [1, 2] . Effective additional therapy to reduce this mortality has been sought for several decades. It has been hypothesized that intravenous immunoglobulin (IVIG) may be beneficial for patients with sepsis because of its broad potential activity against both bacterial products and host cytokines [3] [4] [5] [6] .
The largest randomized trial of IVIG use in patients with sepsis (n = 653) reported to date found that IVIG use did not reduce 28-day mortality compared with placebo [7] . On the other hand, several metaanalyses of randomized trials found that IVIG use decreased mortality in patients with sepsis compared with either placebo or no IVIG [4] [5] [6] 8] . Most metaanalyses found that IVIG use in adult patients with severe sepsis or septic shock was associated with an overall survival benefit compared with placebo or no intervention [3] . However, all of these metaanalyses were limited by heterogeneity, and 2 metaanalyses found that the mortality benefit disappeared when only the well-designed trials were analyzed [6, 9] . The role of IVIG as an adjunctive treatment for severe sepsis or septic shock is therefore still controversial, and IVIG use is not recommended by the current international guidelines for the treatment of sepsis [1] .
We hypothesized that IVIG could be effective for the treatment of pneumonia patients with septic shock. The purpose of this study was to evaluate our hypothesis using the large, nationwide Japanese Diagnosis Procedure Combination (DPC) database.
METHODS
This study was approved by the institutional review board of the University of Tokyo, which waived the requirement for informed patient consent because of the anonymous nature of the data.
IVIG Use in Japan
The Japanese Ministry of Health, Labour and Welfare has approved the clinical use of polyclonal IVIG at no more than 5 g/day for 3 days, while immunoglobulin (Ig)M-enriched IG [10] [11] [12] is not available in Japan. The latest Japanese Guidelines for the Management of Sepsis state that IVIG administration "may be considered" in patients with sepsis (grade 2C level of evidence) [13] .
Data Source
The DPC database includes administrative claims and discharge abstract data for all inpatients discharged from more than 1000 participating hospitals, including 92% (244/266) of all tertiarycare emergency hospitals in Japan [14] [15] [16] . The baseline patient information in the database includes age; sex; and primary diagnosis, comorbidities at admission, and post-admission complications coded with International Classification of Diseases, 10th Revision, codes and written in the Japanese language. Complications that occurred after admission are clearly differentiated from comorbidities that were already present at admission. The DPC database also includes the dosages and dates of all drugs and blood products administered during hospitalization. All interventional and surgical procedures are coded with original Japanese codes. The dates of hospital admission and discharge, surgery, bedside procedures, drugs administered, and discharge status (dead or alive) are recorded using a uniform data submission format. The diagnostic records are linked to the payment system, and the attending physicians are required to report objective evidence for the diagnosis of the disease for reimbursement of treatment [14] [15] [16] .
Patient Selection
We identified mechanically ventilated pneumonia patients with septic shock who were recorded in the DPC database from 1 July 2010 to 31 March 2013. The inclusion criteria for the current analysis were as follows: age ≥18 years; confirmed diagnosis of pneumonia at admission (ie, patients coded as "pneumonia" in the "primary diagnosis" or "comrbidities at admission" sections in the database were included, while patients with pneumonia recorded as a "post-admission complication" were not included in order to exclude hospital-acquired pneumonia or ventilator-associated pneumonia [17] ); and septic shock, defined as use of a vasopressor (noradrenaline and/or dopamine) within 5 days. The exclusion criteria were as follows: pregnancy; trauma, hematologic malignancy, solid tumor, obstetric complication, immunoglobulinopathy, or vascular disorder recorded as a comorbidity at admission; major surgery (under general anesthesia) within 3 days after admission; viral pneumonia (including influenza), aspiration pneumonia, human immunodeficiency virus-related Pneumocystis jirovecii pneumonia, or tuberculous pneumonia; no antibiotic therapy initiated on day 0 or 1; no IVIG in the early phase of treatment (within 5 days after admission); IVIG used at more than the approved dose for sepsis in Japan); and discharge within 2 days of admission.
Variables and Endpoints
In addition to the baseline characteristics at the time of admission, several other variables were evaluated in the current study. The Japan Coma Scale (JCS) score, used to assess the level of consciousness, was recorded for all patients at admission [15] . The JCS score was categorized into 4 groups: 0 (alert), 1-3 (delirium), 10-30 (somnolence), and 100-300 (coma). The hospital type was categorized as academic or nonacademic. Hospital volume was defined as the number of pneumonia patients treated, categorized into tertiles (low, medium, and high).
The endpoints used in the current study were all-cause 28-day mortality; all-cause in-hospital mortality; catecholaminefree days; and ventilator-free days [18] . Catecholamine-and ventilator-free days were defined, respectively, as the number of days alive without catecholamine or mechanical ventilation assistance during the first 28 days after admission; patients who died before day 28 were assigned 0 days [18] .
Statistical Analyses
We performed 1-to-1 matching between the IVIG and control groups based on estimated propensity scores for each patient [19] . To estimate the propensity score, we fitted a logistic regression model for IVIG use as a function of patient demographics and hospital factors including age, sex, hospital type and hospital volume, JCS score, evidence of pleural effusion with drainage, intermittent hemodialysis after admission/continuous renal replacement therapy, extracorporeal membrane oxygenation, catecholamine use, steroid use, antithrombin use, recombinant human soluble thrombomodulin use, initial use of 2 or more antibiotics, each type of antibiotic used, sivelestat sodium use, and blood transfusion [1, 2, 13-16, 18, 20, 21] . The C statistic for evaluating the goodness of fit was calculated. A 1-to-1 matched analysis using nearest-neighbor matching was performed based on the patients' estimated propensity scores. A match occurred when a patient in the IVIG group had an estimated score within 0.2 standard deviations of a patient in the control group [19] . We examined balance in baseline variables using standardized differences, where an absolute standardized difference >10% was regarded as imbalanced [19] . Descriptive statistics are presented for all patients and for propensity score-matched patients. Categorical variables were compared using the χ 2 test or Fisher exact test. To evaluate whether an immortal time bias (ie, a span of cohort follow-up during which the outcome under examination could not occur because of the exposure definition) might be present [22] ), we evaluated the difference in the mortality rates within 5 days after admission between the propensity-matched IVIG cases and the controls. In addition, a Cox regression analysis was used to assess the differences in the in-hospital survival rates between the patients with and without IVIG in the propensity score-matched groups.
We performed a logistic regression analysis fitted with generalized estimating equations in order to examine the association between IVIG use and 28-day mortality, accounting for the paired nature of the propensity score-matched patients, by estimating odds ratios, along with associated confidence intervals (CIs), using methods appropriate for matched data [19, 23] . We used IVIG alone as an independent factor in both the Cox regression and logistic generalized estimating equations analyses in the propensity score-matched groups because all of the measured factors were already balanced among the matched groups, as per previous studies [19, 23] . We also performed instrumental variable analysis as confirmatory analysis for the propensity score analyses [15, 16, 24, 25] . We used the pattern of hospital IVIG use as an instrumental variable and computed the difference in 28-day mortality between the groups with and without IVIG treatment [15, 16, 24] . This approach was implemented using a 2-stage least-squares regression that also adjusted for patient demographic characteristics. We classified hospitals that administered IVIG to the 90th percentile or more of mechanically ventilated pneumonia patients with septic shock as hospitals with a preference for IVIG use; hospitals that administered IVIG to less than the 90th percentile of mechanically ventilated pneumonia patients with septic shock were classified as hospitals without a preference for IVIG use [24] . We estimated the risk difference and 95% CI using the ivreg2 procedure by Stata/SE 13.0 (Stata Corp., College Station, Texas). To confirm that the pattern of hospital IVIG use was not a weak instrument, we used a partial F test [25] . An F statistic >10 suggests that the instrument is not weak [25] . All statistical analyses were performed using IBM SPSS, version 22 (IBM Corp., Armonk, New York) and Stata/SE 13.0.
RESULTS

Patients
A total of 8264 patients treated at 1014 hospitals during the 33-month study period were identified. The patients were divided into an IVIG group (n = 1324) and a control group (n = 6940), from which 1045 propensity score-matched pairs were generated ( Figure 1 ). The C statistic indicated that the goodness of fit was 0.82 (95% CI, .81 to .83) in the propensity score model. Table 1 shows the baseline characteristics of the unmatched and propensity score-matched groups. When the unmatched groups were compared, patients were more likely to receive IVIG if they were younger; were admitted to an academic hospital; and required more noradrenalin, more medications, and blood transfusion. Patients in the IVIG group received more carbapenem, fluoroquinolones, macrolides, and anti-methicillinresistant Staphylococcus aureus (MRSA) drugs and were more likely to receive multiple concomitant antibiotics. After propensity score-matching, the baseline patient characteristics were well balanced between the groups (ie, absolute standardized differences were <10%).
Endpoints
The overall 28-day mortality was 35.7% (2954/8264). There was no significant difference in the mortality rates within 5 days after admission between the propensity-matched IVIG cases and the controls (11.3%, 118/1045 vs 11.7%, 122/1045; difference 0.4%; 95% CI, −2.3 to 3.1). The 28-day mortality rate was not significantly different between the IVIG and control groups in the unmatched analysis (37.8%, 501/1324 vs 35.3%, 2453/6940; difference, 2.5%; 95% CI, −.3 to 5.3) or the propensity scorematched analysis (36.7%, 383/1045 vs 36.0%, 376/1045; difference, 0.7%; 95% CI, −3.5 to 4.8; Table 2 ). Logistic regression analysis did not show a significant association between IVIG use and 28-day mortality in propensity score-matched patients Table 3 ). In the instrumental variable model, the null hypothesis that there was no association between the pattern of hospital IVIG use and actual IVIG use was rejected (P < .001; F statistic, 827). The reduction in 28-day mortality was not significantly associated with IVIG use (difference, −3.1%; 95% CI, −13.2 to 7.0). There were no significant differences in in-hospital mortality between the IVIG and control groups in unmatched patients (48.8%, 646/ 1324 vs 47.1%, 3269/ 6940; difference, 1.7%; 95% CI, −1.3 to 4.6) or propensity score-matched patients (47.9%, 501/ 1045 vs 46.7%, 488/ 1045; difference, 1.2%; 95% CI, −3.0 to 5.5). Cox regression analysis showed no significant difference in in-hospital mortality between the 2 groups (hazard ratio, 1.00; 95% CI, .89 to 1.14).
There were fewer catecholamine-free days in the IVIG group than in the control group for unmatched patients (11.3 vs 12.1; difference, −0.78; 95% CI, −1.5 to −.10); however, no significant differences were documented in the propensity score-matched groups (11.5 vs 12.3 days; difference, −0.82; 95% CI, −1.8 to .15). Although there were fewer ventilator-free days in the IVIG group than in the control group for unmatched patients (8.3 vs 9.4; difference, −1.1; 95% CI, −1.7 to −.53), no significant differences were documented in the propensity score-matched groups (8.7 vs 9.1 days; difference, −0.47; 95% CI, −1.3 to .38).
DISCUSSION
In the current study, propensity score and instrumental variable analyses were performed using data from a large nationwide database. The results suggest that there was no significant association between IVIG use and mortality in mechanically ventilated pneumonia patients with septic shock. In addition, we documented no significant association between IVIG use and catecholamine-or ventilator-free days. The methodological strength of this study lies in the evaluation of IVIG use for severe pneumonia, which is the most common cause of sepsis [2, [26] [27] [28] , in a large number of mechanically ventilated pneumonia patients with septic shock. The baseline characteristics and concomitant treatments that can potentially affect mortality in patients with sepsis and pneumonia (including types of antibiotics) with and without IVIG were evaluated. A recent review suggested that the accuracy of antibiotic usage is a critically important factor when evaluating the effect of IVIG [29] . In the present study, the proportions of overall initial antibiotics given to the patients were as follows: 2 or more antibiotics (32.8%); carbapenem (38.4%); piperacillintazobactam (18.4%); fluoroquinolone (15.4%); macrolide (6.7%); and anti-MRSA drugs (5.1%). We speculate that the high proportions of carbapenem, piperacillin-tazobactam, fluoroquinolone, and anti-MRSA drugs may reflect their administration as empiric therapy because patients who require both vasopressors and mechanical ventilation are more likely to have risk factors for resistant pathogens, including community-associated MRSA and Pseudomonas aeruginosa [13, 30, 31] . In addition, antibiotics with a broad-spectrum regimen and adequate coverage against typical causative organisms are recommended for empiric therapy in septic shock patients, according to the current sepsis guidelines [1, 13] . All of the variables listed in Table 1 , including the types of antibiotics, were well balanced after the propensity score-matching process.
However, our propensity score-matched analysis failed to confirm our hypothesis that IVIG use could improve mortality in patients with severe pneumonia. These findings were robust with regard to the results obtained by the logistic generalized estimating equations and Cox regression analyses. To overcome the bias of unmeasured confounding factors, we also performed instrumental variable analysis, which confirmed the robustness of our results.
In 2000, Masaoka et al [32] conducted an open-label trial to test the effectiveness of IVIG use (5 g/day for 3 days) in Japanese patients with sepsis (n = 682). The proportion of patients with decreased fever was higher in the IVIG group than in the control group, but the researchers did not evaluate mortality as an endpoint [32] . Based on the results of that study, the Japanese government approved IVIG for clinical use in patients with sepsis. However, to our knowledge, no large nationwide study showing that IVIG use is effective in reducing mortality has been reported in Japan to date. In addition, it may be unfeasible to conduct new randomized trials to evaluate the efficacy of IVIG for septic shock in Japan because IVIG is already widely used in clinical practice.
The results of previous studies suggest that there is still insufficient evidence to support the hypothesis that IVIG use is beneficial in patients with sepsis [3, 4, 6, 33] . The most recent Surviving Sepsis Campaign guidelines [1] therefore do not suggest IVIG use in patients with sepsis (grade 2B level of evidence). In contrast, the Japanese Guidelines for the Management of Sepsis suggest that IVIG use "may be considered" in patients with sepsis (grade 2C level of evidence) [13] . Our results support the Surviving Sepsis Campaign guidelines [1] and the findings of the largest trial of IVIG use, which reported an insignificant trend in favor of IVIG use in terms of mortality in patients with sepsis due to pneumonia [7] . The findings of the current nationwide study provide additional data from a country where IVIG is still commonly used for sepsis.
There are several kinds of IVIG [4] -monoclonal, polyclonal IVIG [7, 34] , and IgM-enriched IVIG [10] [11] [12] 35] . In Japan, polyclonal IVIG is approved for clinical use for sepsis, but monoclonal and IgM-enriched IG are not available. Importantly, the dosage of IVIG used in Japan (ie, 5 g/day for 3 days) is very low compared with the IVIG dosages used in international studies [7, 34] . For example, in the study by Darenberg et al [34] , polyclonal IVIG was provided intravenously for 3 consecutive days at 1 g/kg body weight on day 1 and 0.5 g/kg body weight on days 2 and 3. In the study by Werdan et al [7] , a total dose of 900 mg/kg body weight was used. The low doses of IVIG may be used only in Asian countries including Japan and Korea. However, our results suggest that approximately 16% of the 8264 patients evaluated in the present study received the indicated low dose of IVIG for their treatment. These are "realworld" results for the use of IVIG reported from 1014 hospitals throughout Japan.
Several limitations must be considered when interpreting the results of this study. First, although the study population is large, the study was conducted retrospectively in an observational manner without randomization. Although a propensity score-matching method was used to adjust for differences in baseline characteristics and disease severity, bias could still be present in the form of confounders that were not measured. In-hospital mortality (Cox regression analysis)
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We performed a logistic regression analysis fitted with generalized estimating equations (GEEs) in order to examine the association between intravenous immunoglobulin (IVIG) use and 28-day mortality and to account for the paired nature of the propensity score-matched patients. We used only the binary variable of the IVIG or control group as an independent variable; the dependent variable was 28-day death in the logistic GEE analysis and the time to in-hospital death in the Cox regression analysis.
Important examples of such confounders are the acute physiology and chronic health evaluation score, ratio of arterial oxygen partial pressure to fractional inspired oxygen, ventilator settings, positive end-expiratory pressure, and extravascular lung water [2, 36, 37] . Unfortunately, these data are not available from the DPC database. Our results were therefore additionally validated using instrumental variable analysis to compensate for these potential unmeasured confounders. Second, this study focused on severe pneumonia, and the results cannot be generalized to patients with other causes of sepsis, such as infection of the digestive or urinary tract, streptococcal toxic shock syndrome, or necrotizing fasciitis [34, 38, 39] . Third, the IVIG dosage in Japan is less than that referred to in previously reported trials and studies, as mentioned earlier. Underdosage compared with internationally recommended dosages might be the reason for the negative data.
CONCLUSIONS
This nationwide retrospective study found no apparent significant association between IVIG use and mortality in patients with severe pneumonia who required mechanical ventilation and vasopressors-at least for the dose clinically used in Japan. Further studies are required to clarify the role of IVIG treatment in patients with sepsis from other causes.
Notes
